Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune to resubmit twice-rejected drug for approval after FDA shakeup
941.09MUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US76029N1063
CUSIP
76029N106
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
March
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
2.01
Dividend Share
-
Dividend Yield
-
Earnings Share
-3.69
Wall Street Target Price
13.00
EPS Estimate Current Year
-3.28
EPS Estimate Next Year
-2.09
EPS Estimate Current Quarter
-0.545
EPS Estimate Next Quarter
-0.62
Most Recent Quarter
-
Revenue TTM
0
Gross Profit TTM
0
EBITDA
-312,555,008
Profit Margin
0.00%
Return On Assets TTM
-45.03%
Return On Equity TTM
-107.88%
Revenue Per Share TTM
0
Qtly Revenue Growth YOY
0.00%
Diluted Eps TTM
-3.69
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
0
Price Book MRQ
5.6562
Enterprise Value Revenue
0
Enterprise Value EBITDA
0
93.40
3.46%23.27
1.13%875.30
0.85%772.11
0.46%197.81
0.26%865.00
0.00%269.84
0.00%129.33
-2.17%57.26
-0.85%484.03
-0.17%